Will the FDA be approving ipilimumab relatively soon?

Apparently the U.S. Food & Drug Administration (FDA) has canceled a  meeting of the Oncology Drugs Advisory Committee (ODAC) that had been scheduled for February 9. The meeting was originally intended to discuss issues related to a biologics license application for ipilimumab (trade name Yervoy™).

The “New” Prostate Cancer InfoLink believes that the cancellation of this meeting of ODAC implies that we can expect to see the FDA approve the marketing of ipilimumab relatively early in 2011. According to the FDA the meeting was canceled “because the issues for which the FDA was seeking the scientific input of the committee have been resolved.”

The initial indication of ipilimumab will have nothing to do with prostate cancer. This interesting new drug will initially be approved for the management of patients with advanced forms of melanoma (an aggressive type of skin cancer characterized by the development of dark, uneven, mole-like lesions). However, there have been some interesting data reported on the activity of ipilimumab in high-risk and progressive prostate cancer.

Ipilimumab is currently in clinical trials for the treatment of several stages of prostate cancer. Examples of these trials include:

If ipilimumab is approved for the treatment of melanoma, physicians will be at liberty to prescribe this drug “off-label” for the treatment of other appropriate conditions, potentially including prostate cancer. Of course insurance companies may not be willing to cover costs associated with ipilimumab therapy for prostate cancer until there are data clearly showing that it is effective and safe in the management of this condition.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: